A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma
Public ClinicalTrials.gov record NCT05451810. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Open-Label Trial to Evaluate Safety of Epcoritamab Monotherapy in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma (Previously Grade 1-3a) When Administered in the Outpatient Setting
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). Classic Follicular Lymphoma is a slow-growing type of non-Hodgkin lymphoma. The purpose of this study is to assess the safety of epcoritamab in adult participants in relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL) who have received at least 1 prior line of systemic antilymphoma therapy including at least 1 anti-CD20 monoclonal antibody-containing therapy or R/R classic follicular lymphoma (cFL). Adverse events will be assessed. Epcoritamab is an investigational drug being developed for the treatment of R/R DLBCL and R/R cFL. Study doctors will assess participants in a monotherapy treatment arm of epcoritamab. Participants will receive escalating doses of epcoritamab, until full dose is achieved. Approximately 184 adult participants with R/R DLBCL and R/R cFL will be enrolled in the study in approximately 80 sites in the United States of America. Participants will receive escalating doses of subcutaneous epcoritamab, until full dose is achieved, in 28-day cycles. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.
Study identification
- NCT ID
- NCT05451810
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 184 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 17, 2022 (Actual)
- Primary completion
- Mar 2027 (Estimated)
- Completion
- Mar 2027 (Estimated)
- Last update posted
- Sep 11, 2026
2022 – 2027
United States locations
- U.S. sites
- 70
- U.S. states
- 32
- U.S. cities
- 63
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Infirmary Health - Infirmary Cancer Care at Mobile Infirmary /ID# 264630 | Mobile | Alabama | 36607 | — |
| University of Arkansas for Medical Sciences /ID# 244562 | Little Rock | Arkansas | 72205 | — |
| Highlands Oncology Group, PA /ID# 245002 | Springdale | Arkansas | 72762 | — |
| Beverly Hills Cancer Center /ID# 255327 | Beverly Hills | California | 90211 | — |
| Compassionate Cancer Care Research Group - Fountain Valley /ID# 246133 | Fountain Valley | California | 92708-7501 | — |
| UCSF Fresno /ID# 263286 | Fresno | California | 93701-2302 | — |
| University of California, Los Angeles /ID# 244573 | Los Angeles | California | 90095 | — |
| Rocky Mountain Cancer Centers - Boulder /ID# 247653 | Boulder | Colorado | 80303 | — |
| Bennett Cancer Center - Stamford Hospital /ID# 244530 | Stamford | Connecticut | 06902-3602 | — |
| MedStar Washington Hospital Center /ID# 246068 | Washington D.C. | District of Columbia | 20010 | — |
| Cancer Specialists of North Florida /ID# 261842 | Jacksonville | Florida | 32256 | — |
| Florida Cancer Specialists /ID# 260854 | Lake Mary | Florida | 32746-2115 | — |
| Mount Sinai Medical Center-Miami Beach /ID# 249045 | Miami Beach | Florida | 33140-2948 | — |
| Memorial Hospital West /ID# 248432 | Pembroke Pines | Florida | 33028 | — |
| BRCR Medical Center Inc /ID# 262527 | Tamarac | Florida | 33321-2919 | — |
| Cleveland Clinic Florida /ID# 244532 | Weston | Florida | 33331-3609 | — |
| Emory University, Winship Cancer Institute /ID# 246056 | Atlanta | Georgia | 30322 | — |
| University of Illinois at Chicago /ID# 245038 | Chicago | Illinois | 60607 | — |
| Illinois Cancer Specialists /ID# 247655 | Niles | Illinois | 60714 | — |
| Parkview Comprehensive Cancer Center /ID# 244545 | Fort Wayne | Indiana | 46845 | — |
| Indiana Blood & Marrow Transpl /ID# 244971 | Indianapolis | Indiana | 46237 | — |
| University of Iowa Health Care /ID# 258227 | Des Moines | Iowa | 50314-3017 | — |
| Our Lady Of The Lake Regional Medical Center /ID# 255008 | Baton Rouge | Louisiana | 70808 | — |
| American Oncology Partners of Maryland /ID# 244968 | Bethesda | Maryland | 20817 | — |
| Maryland Oncology Hematology /ID# 254192 | Columbia | Maryland | 21044-3128 | — |
| Tufts Medical Center /ID# 246074 | Boston | Massachusetts | 02111-1552 | — |
| Massachusetts General Hospital /ID# 245239 | Boston | Massachusetts | 02114 | — |
| Beth Israel Deaconess Medical Center /ID# 248651 | Boston | Massachusetts | 02215-5400 | — |
| Cancer & Hematology Centers of Western Michigan - East /ID# 244985 | Grand Rapids | Michigan | 49546-7062 | — |
| Trinity Health St. Joseph Mercy Ann Arbor /ID# 244547 | Ypsilanti | Michigan | 48197-1051 | — |
| Hattiesburg Clinic /ID# 244980 | Hattiesburg | Mississippi | 39401 | — |
| St. Luke's Hospital - Chesterfield /ID# 247815 | Chesterfield | Missouri | 63017 | — |
| NHO - Nebraska Hematology-Oncology /ID# 263164 | Lincoln | Nebraska | 68506 | — |
| Dartmouth-Hitchcock Medical Center - 1 Medical Center Drive /ID# 245003 | Lebanon | New Hampshire | 03756 | — |
| The John Theurer Cancer /ID# 262532 | Hackensack | New Jersey | 07601 | — |
| Morristown Medical Center /ID# 244973 | Morristown | New Jersey | 07960-6136 | — |
| University of New Mexico /ID# 252434 | Albuquerque | New Mexico | 87102-4517 | — |
| New York Cancer & Blood Specialists - Lake Success Medical Oncology /ID# 264681 | New Hyde Park | New York | 11042 | — |
| Stony Brook University Medical Center /ID# 244631 | New York | New York | 10021 | — |
| New York Cancer and Blood Specialists - New York /ID# 264676 | New York | New York | 10028 | — |
| Icahn School of Medicine at Mount Sinai /ID# 258610 | New York | New York | 10029 | — |
| Memorial Sloan Kettering Cancer Center-Koch Center /ID# 244628 | New York | New York | 10065-6007 | — |
| New York Cancer and Blood Specialists /ID# 259016 | Port Jefferson Station | New York | 11776-8060 | — |
| New York Cancer and Blood Specialists - Bronx /ID# 264690 | The Bronx | New York | 10469 | — |
| East Carolina University - Brody School of Medicine /ID# 248989 | Greenville | North Carolina | 27834 | — |
| Wake Forest Univ HS /ID# 245005 | Winston-Salem | North Carolina | 27157 | — |
| Oncology Hematology Care, Inc. /ID# 246182 | Cincinnati | Ohio | 45236-2725 | — |
| OhioHealth Arthur G.H. Bing, MD Cancer Center /ID# 260803 | Columbus | Ohio | 43214-3908 | — |
| Toledo Clinic Cancer Center - Main /ID# 246852 | Toledo | Ohio | 43623 | — |
| University of Oklahoma, Stephenson Cancer Center /ID# 244568 | Oklahoma City | Oklahoma | 73104-5418 | — |
| Willamette Valley Cancer Institute and Research Center /ID# 246410 | Eugene | Oregon | 97401-6043 | — |
| Oregon Oncology Specialists in Salem /ID# 260570 | Salem | Oregon | 97301-3975 | — |
| Lehigh Valley Hospital-Cedar Crest /ID# 244984 | Allentown | Pennsylvania | 18103-6202 | — |
| Spoknwrd Clinical Trials /ID# 265232 | Easton | Pennsylvania | 18045 | — |
| Penn State Milton S. Hershey Medical Center /ID# 244979 | Hershey | Pennsylvania | 17033-2360 | — |
| UPMC Hillman Cancer Ctr /ID# 244571 | Pittsburgh | Pennsylvania | 15232 | — |
| Reading Hospital; McGlinn Cancer Institute /ID# 259181 | West Reading | Pennsylvania | 19611-2143 | — |
| Prisma Health /ID# 247654 | Greenville | South Carolina | 29605 | — |
| The West Clinic /ID# 245004 | Memphis | Tennessee | 38120 | — |
| Vanderbilt University Medical Center /ID# 260953 | Nashville | Tennessee | 37232 | — |
| Texas Oncology - Austin Midtown /ID# 247656 | Austin | Texas | 78705 | — |
| Texas Oncology-Presbyterian Cancer Center Dallas /ID# 262659 | Dallas | Texas | 75231 | — |
| Texas Oncology - Dallas - Worth Street /ID# 262956 | Dallas | Texas | 75246 | — |
| University of Texas Southwestern Medical Center /ID# 244552 | Dallas | Texas | 75390-7208 | — |
| Texas Oncology - San Antonio Medical Center /ID# 247658 | San Antonio | Texas | 78240-5251 | — |
| Texas Oncology - Northeast Texas /ID# 247657 | Tyler | Texas | 75702 | — |
| Virginia Cancer Specialists - Gainesville /ID# 248760 | Gainesville | Virginia | 20155-3257 | — |
| Virginia Oncology Associates - Norfolk (Lake Wright) /ID# 265514 | Norfolk | Virginia | 23502 | — |
| Blue Ridge Cancer Center /ID# 260597 | Roanoke | Virginia | 24014-2419 | — |
| Northwest Medical Specialties - Tacoma /ID# 245045 | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05451810, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 11, 2026 · Synced Nov 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05451810 live on ClinicalTrials.gov.